Cargando…

Comparative-effectiveness of vancomycin and linezolid as part of guideline-recommended empiric therapy for healthcare-associated pneumonia

BACKGROUND: Linezolid has been directly compared to vancomycin in pneumonia; however, most clinical trials have not compared outcomes specifically in the healthcare-associated pneumonia (HCAP) population. The objective of this study was to compare the effectiveness of vancomycin and linezolid in a n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Reveles, Kelly R., Mortensen, Eric M., Attridge, Russell T., Frei, Christopher R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4573683/ https://www.ncbi.nlm.nih.gov/pubmed/26382940 http://dx.doi.org/10.1186/s13104-015-1396-1

Ejemplares similares

Application of a methicillin-resistant Staphylococcus aureus risk score for community-onset pneumonia patients and outcomes with initial treatment
por: Teshome, Besu F., et al.
Publicado: (2015)

Linezolid vs Vancomycin in Induced Thrombocytopenia
por: Al-Harbi, Dimah, et al.
Publicado: (2022)

Pneumonia Caused by Community-Acquired Methicillin-Resistant Staphylococcus aureus: Vancomycin or Linezolid?
por: Tian, Ye, et al.
Publicado: (2018)

Empiric guideline-recommended weight-based vancomycin dosing and mortality in methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study
por: Hall, Ronald G, et al.
Publicado: (2012)

Comparison of Empiric Antibiotic Escalation Therapy with Vancomycin (VAN) versus Linezolid (LIN) in Patients with Febrile Neutropenia
por: Mayer, Karin, et al.
Publicado: (2022)

Treatment of hospital-acquired pneumonia with linezolid or vancomycin: a systematic review and meta-analysis
por: Kalil, Andre C, et al.
Publicado: (2013)

No Outbreak of Vancomycin and Linezolid Resistance in Staphylococcal Pneumonia over a 10-Year Period
por: Yayan, Josef, et al.
Publicado: (2015)

Activity of vancomycin combined with linezolid against clinical vancomycin-resistant Enterococcus strains
por: Aktas, Gulseren
Publicado: (2020)

Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study
por: Hall, Ronald G, et al.
Publicado: (2013)

Linezolid to treat urinary tract infections caused by vancomycin-resistant Enterococcus
por: Pontefract, Benjamin Alan, et al.
Publicado: (2020)

An economic model to compare linezolid and vancomycin for the treatment of confirmed methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany
por: Patel, Dipen A, et al.
Publicado: (2014)

Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin
por: Estes, Kerry S, et al.
Publicado: (2010)

Optimization of nebulized delivery of linezolid, daptomycin, and vancomycin aerosol
por: Zarogoulidis, Paul, et al.
Publicado: (2014)

Intravitreal linezolid in the management of vancomycin-resistant enterococcal endophthalmitis
por: Babalola, Olufemi Emmanuel
Publicado: (2020)

1470. Linezolid for Treatment of Urinary Tract Infections Caused by Vancomycin-resistant Enterococci
por: Pontefract, Benjamin, et al.
Publicado: (2019)

Outpatient antibiotic prescribing in the United States: 2000 to 2010
por: Lee, Grace C, et al.
Publicado: (2014)

Linezolid for the Treatment of Urinary Tract Infections Caused by Vancomycin-Resistant Enterococci
por: Wingler, Mary Joyce, et al.
Publicado: (2021)

Clinical response and hospital costs associated with the empirical use of vancomycin and linezolid for hospital-acquired pneumonia in a Chinese tertiary care hospital: a retrospective cohort study
por: Song, Yuanlin, et al.
Publicado: (2014)

Nosocomial methicillin-resistant staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy
por: Pletz, Mathias W, et al.
Publicado: (2010)

1881. Empiric Pseudomonal Monotherapy vs. Combination Therapy for Community-Onset Pneumonia in Older Adults
por: Obodozie-Ofoegbu, Obiageri, et al.
Publicado: (2018)

Comparison of linezolid and daptomycin for the treatment of vancomycin-resistant enterococcal bacteremia
por: Narayanan, Navaneeth, et al.
Publicado: (2019)

Modeling the economic impact of linezolid versus vancomycin in confirmed nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus
por: Patel, Dipen A, et al.
Publicado: (2014)

Clindamycin Plus Vancomycin Versus Linezolid for Treatment of Necrotizing Soft Tissue Infection
por: Dorazio, Joshua, et al.
Publicado: (2023)

1045 Linezolid Compared to Daptomycin for the Treatment of Vancomycin-resistant Enterococcal Urinary Tract Infections
por: Moenster, Ryan P., et al.
Publicado: (2014)

Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients
por: Fernández-Barat, Laia, et al.
Publicado: (2019)

Optimization of Linezolid Dosing Regimens for Treatment of Vancomycin-Resistant Enterococci Infection
por: Santimaleeworagun, Wichai, et al.
Publicado: (2021)

Sequential Therapy of Linezolid and Contezolid to Treat Vancomycin-Resistant Enterococcus faecium Pneumonia in a Centenarian Patient: Case Report
por: Chen, Pengzhi, et al.
Publicado: (2023)

Disparities of Care for African-Americans and Caucasians with Community-Acquired Pneumonia: A Retrospective Cohort Study
por: Frei, Christopher R, et al.
Publicado: (2010)

662. In vitro antibacterial activity of contezolid compared to linezolid and vancomycin in clinical isolates from China
por: Wang, Shanmei, et al.
Publicado: (2022)

Risk Factors and Outcomes Associated With Acquisition of Daptomycin and Linezolid–Nonsusceptible Vancomycin-Resistant Enterococcus
por: Greene, Matthew H, et al.
Publicado: (2018)

Sequential Therapy of Linezolid and Contezolid to Treat Vancomycin-Resistant Enterococcus faecium Pneumonia in a Centenarian Patient: Case Report [Corrigendum]
Publicado: (2023)

1221. Genomic Factors Affecting the Efficacy of Antimicrobial Therapy in Daptomycin-, Linezolid-, Vancomycin-Resistant Enterococcus faecium (DLVRE)
por: Gatesy, Samuel W, et al.
Publicado: (2021)

Empirical cefepime+vancomycin versus ceftazidime+vancomycin versus meropenem+vancomycin in the treatment of healthcare-associated meningitis: results of the multicenter Ephesus study
por: Sipahi, Oguz Resat, et al.
Publicado: (2023)

Effectiveness, safety, and cost of vancomycin and linezolid in Kuwait: A retrospective cohort study
por: Alghanem, Sarah S., et al.
Publicado: (2023)

Comparative Efficacies of Linezolid vs. Tedizolid in an Experimental Murine Model of Vancomycin-Resistant Enterococcal (VRE) Bacteremia
por: Abdelhady, Wessam, et al.
Publicado: (2019)

Emergence of linezolid- and vancomycin-resistant Enterococcus faecium in a department for hematologic stem cell transplantation
por: Krull, M., et al.
Publicado: (2016)

1250. Development of Linezolid and Daptomycin Resistance in Vancomycin Resistant Enterococcus faecium (VRE) during prolonged treatment for Intraabdominal Abscess
por: Al-Heeti, Omar, et al.
Publicado: (2021)

799 Linezolid vs Vancomycin in the Treatment of Nosocomial Pneumonia: A Cost-effectiveness Analysis Incorporating Results from the ZEPHyR Trial
por: Collins, Curtis, et al.
Publicado: (2014)

Breakthrough daptomycin-, linezolid-, vancomycin-resistant Enterococcus faecium bacteremia during protracted daptomycin therapy: A case report
por: Pincus, Nathan B., et al.
Publicado: (2022)

In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci
por: El-Azizi, Mohamed, et al.
Publicado: (2005)

Cannot write session to /tmp/vufind_sessions/sess_c579gg6ct8v2fi6jv7iivpnb6t